Revvity (NYSE:RVTY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase & Co.

Revvity (NYSE:RVTY) had its price target decreased by investment analysts at JPMorgan Chase & Co. from $105.00 to $96.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 11.61% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. The Goldman Sachs Group began coverage on Revvity in a report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 price objective on the stock. Wall Street Zen upgraded Revvity from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. TD Cowen reissued a “hold” rating on shares of Revvity in a research note on Tuesday, February 3rd. Finally, Barclays lifted their target price on Revvity from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $112.92.

Revvity Trading Up 1.5%

Shares of NYSE RVTY traded up $1.23 during trading on Tuesday, hitting $86.01. 233,533 shares of the company were exchanged, compared to its average volume of 1,325,249. Revvity has a 12-month low of $81.36 and a 12-month high of $118.30. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68. The company has a fifty day moving average price of $97.61 and a 200-day moving average price of $96.56. The firm has a market capitalization of $9.62 billion, a PE ratio of 41.42, a P/E/G ratio of 1.78 and a beta of 1.10.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.55 by $0.15. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The firm had revenue of $772.06 million for the quarter, compared to analysts’ expectations of $759.81 million. During the same quarter in the previous year, the company posted $1.42 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. As a group, equities research analysts expect that Revvity will post 4.94 EPS for the current year.

Institutional Trading of Revvity

Several institutional investors have recently added to or reduced their stakes in RVTY. CYBER HORNET ETFs LLC acquired a new position in Revvity during the second quarter worth $32,000. Cromwell Holdings LLC grew its stake in shares of Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after buying an additional 198 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in shares of Revvity in the 2nd quarter valued at $34,000. Headlands Technologies LLC acquired a new position in Revvity during the 2nd quarter worth about $49,000. Finally, Los Angeles Capital Management LLC acquired a new position in Revvity during the 4th quarter worth about $51,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.